Impact of BRAF Gene Mutation in Nonmetastatic Colorectal Cancer on Disease Progression and Survival Outcomes
Journal of Gastroenterology and Hepatology · 2026
DOI: 10.1111/jgh.70215 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Gastroenterology and Hepatology, 2026. Verfasst von Caroline Lum und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anatomy and Developmental Biology, Monash University, Clayton, Australia. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins B-raf, Colorectal Neoplasms, Mutation. Die Arbeit nennt 35 Literaturangaben. Gefördert von: Let's Beat Bowel Cancer.
Abstract (Originalsprache)
Background and Aim Colorectal cancer (CRC) is a major global health concern, with molecular and histopathological subtypes influencing disease progression. Mutations in the v‐Raf murine sarcoma viral oncogene homolog B (BRAF) gene, particularly the V600E variant, define a subset associated with aggressive features. The impact of BRAF mutations on early‐stage CRC prognosis and their interaction with mismatch repair (MMR) status remains less characterized.
Methods
We conducted a retrospective analysis of prospectively collected data from two tertiary institutions on Stage II–III CRC patients. BRAF/MMR subgroups were defined (BRAFmut/pMMR, BRAFmut/dMMR, BRAFwt/pMMR, and BRAFwt/dMMR). Associations with patient/tumor characteristics, adjuvant treatment, and long‐term outcomes were assessed. Univariate and multivariate analyses were used to evaluate disease recurrence and mortality.
Results
Of 157 eligible patients, univariate analyses indicated poorer outcomes for those with pMMR CRC. Multivariate analysis examining disease recurrence and death highlights that pMMR patients perform worse, but significantly, this analysis revealed that BRAFmut is a significant predictor of mortality in the nonmetastatic setting, irrespective of MMR status.
Conclusions
Nonmetastatic BRAFmut CRC carries a dismal prognosis, irrespective of MMR status. Routine testing for BRAF V600E mutation alongside MMR assessment is advocated to inform personalized management, potentially impacting surveillance, adjuvant therapy decisions, and eligibility for targeted therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anatomy and Developmental Biology, Monash University, Clayton, Australia.
- Stem Cells and Development Program, Monash Biomedicine Discovery Institute, Monash University, Clayton, Australia.
- Department of Oncology, Monash Health, Clayton, Australia.
- Cabrini Research, Cabrini Health, Malvern, Australia.
- School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.
- Department of Psychiatry, School of Clinical Sciences, Monash University, Clayton, Australia.
ORCID-Profile: Caroline Lum, Harrison Boka, Mohammad Asghari-Jafarabadi, Shehara Mendis, Lauren Cohen, Helen E Abud, Rebekah M Engel
Förderung
- Let's Beat Bowel Cancer
Zitieren
APA
Lum, C., Boka, H., Asghari-Jafarabadi, M., Mendis, S., Cohen, L., Abud, H. E., Engel, R. M., & McMurrick, P. J. (2026). Impact of BRAF Gene Mutation in Nonmetastatic Colorectal Cancer on Disease Progression and Survival Outcomes. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.70215
Vancouver
Lum C, Boka H, Asghari-Jafarabadi M, Mendis S, Cohen L, Abud HE, et al. Impact of BRAF Gene Mutation in Nonmetastatic Colorectal Cancer on Disease Progression and Survival Outcomes. Journal of Gastroenterology and Hepatology. 2026. doi:10.1111/jgh.70215
BibTeX
@article{Lum2026,
author = {Lum, Caroline and Boka, Harrison and Asghari-Jafarabadi, Mohammad and Mendis, Shehara and Cohen, Lauren and Abud, Helen E and Engel, Rebekah M and McMurrick, Paul J},
title = {Impact of BRAF Gene Mutation in Nonmetastatic Colorectal Cancer on Disease Progression and Survival Outcomes},
journal = {Journal of Gastroenterology and Hepatology},
year = {2026},
doi = {10.1111/jgh.70215}
}
EUVIMED